Prospective Cohort of Acute Cardiology Referrals in an Ambulatory Day-Hospital Setting (CESAR)
CESAR Study: Prospective Cohort of Consecutive Patients Undergoing Cardiologic Evaluation in a Specialized Ambulatory Referral Unit
Suspected acute or subacute cardiovascular diseases-including chest pain, dyspnea, and palpitations-are among the most common reasons for unscheduled emergency department visits and pre-hospital referrals. Despite this high clinical burden, the diagnostic yield is often limited, with a frequent mismatch between initial clinical suspicion and final diagnosis, contributing to substantial healthcare utilization and hospitalization rates. Current evidence is largely focused on specific conditions such as acute coronary syndromes, heart failure, arrhythmias, or pulmonary embolism, and rarely integrates the full spectrum of clinical, biological, and imaging data obtained during initial evaluation.
To address this gap, we will establish a prospective cohort of all consecutive patients referred to the ambulatory day-hospital cardiology unit at Lariboisière University Hospital. This unit acts as a specialized downstream referral structure within the emergency care pathway, receiving patients after triage by emergency physicians, pre-hospital regulation services (SAMU), mobile intensive care units (SMUR), or emergency departments. Although it does not capture all suspected cardiovascular emergencies, it represents a selected real-world population deemed to require specialized acute cardiology assessment.
The primary objective is to assess the frequency of cardiac conditions diagnosed in this cohort. Secondary objectives include characterization of patient profiles and diagnostic pathways; evaluation of the diagnostic and prognostic performance of clinical, biological, imaging, and multimodal parameters using final Heart Team diagnosis as reference; analysis of prior health history and healthcare utilization; and assessment of the medico-economic burden of suspected acute cardiovascular disease. The study will further support the development of a dedicated biobank and the validation of next-generation biomarkers, including AI-driven and voice-based markers, as well as decision-support algorithms for binary classification of cardiac involvement. Through integration of multimodal data and linkage with national health records, this approach aims to improve diagnostic accuracy, risk stratification, and understanding of the healthcare impact of acute cardiovascular presentations in a real-world setting.
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Ilmoittautuminen
Yhteystiedot ja paikat
Opiskeluyhteys
Opiskeluyhteys
- Nimi: Théo PEZEL, MD, PhD
- Puhelinnumero: +33 1 49 95 8224
- Sähköposti: theo.pezel@aphp.fr
Tutki yhteystietojen varmuuskopiointi
- Nimi: Julien HUDELO, MD
- Sähköposti: juhudelo@gmail.com
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Näytteenottomenetelmä
Tutkimusväestö
Kuvaus
Inclusion Criteria:
- The study will include all consecutive patients referred to ambulatory day-hospital unit for suspicion of acute or sub-acute cardiovascular disease at the Cardiology Department of Lariboisière University Hospital.
Exclusion Criteria:
- Patient unable to provide informed consent
- Patient not affiliated to French social security
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Aikaikkuna |
|---|---|
|
Proportion of patients with confirmed cardiovascular diagnosis among consecutive patients consulting for suspicion of acute or sub-acute cardiovascular disease at the ambulatory day-hospital unit.
Aikaikkuna: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
Toissijaiset tulostoimenpiteet
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Proportion referred to cardiac computed tomography (CCT)
Aikaikkuna: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Proportion referred to cardiovascular magnetic resonance (CMR)
Aikaikkuna: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Proportion referred to stress tests.
Aikaikkuna: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Proportion referred to Holter monitoring or implantable loop recorders
Aikaikkuna: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Proportion with introduction of heart failure (HF) therapy
Aikaikkuna: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Proportion with introduction of anti-platelet therapy
Aikaikkuna: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Proportion with introduction of anti-coagulant therapy
Aikaikkuna: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Proportion referred to percutaneous coronary intervention (PCI)
Aikaikkuna: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Proportion referred to cardiac surgery
Aikaikkuna: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Proportion referred to electrical cardioversion
Aikaikkuna: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Proportion referred to catheter ablation
Aikaikkuna: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Proportion referred to pacemaker implantation
Aikaikkuna: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Proportion referred to defibrillator implantation
Aikaikkuna: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Diagnostic performance of each initial parameter with: sensitivity, specificity, positive predictive value, negative predictive value, and area under the ROC curve.
Aikaikkuna: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Cost of care pathways initial and up to 2-5 years
Aikaikkuna: From enrollement to five years of follow-up.
|
From enrollement to five years of follow-up.
|
|
|
Prognostic value of baseline features to predict medical events annually up to 10 years of follow-up
Aikaikkuna: From enrollement to ten years of follow-up.
|
The occurrence of:
n. Electrophysiological studies (catheter ablation, pacemaker / defibrillator implantation...) |
From enrollement to ten years of follow-up.
|
|
Cost-effectiveness of the CESAR care pathway
Aikaikkuna: From enrollement to five years of follow-up.
|
Cost-effectiveness of the CESAR care pathway compared with a propensity score-matched control population extracted from the French national health claims database.
|
From enrollement to five years of follow-up.
|
|
F1 score of the artificial intelligence model for detecting cardiac involvement
Aikaikkuna: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Prognostic value of voice-derived acoustic and speech parameters
Aikaikkuna: At enrollement (D0).
|
The occurrence of: a. All-cause mortality b.
Cardiovascular mortality c.
Sudden cardiac death d.
Hospitalization for any cardiovascular reason and duration of hospitalization
|
At enrollement (D0).
|
|
Number of sick leave
Aikaikkuna: From enrollement to five years of follow-up.
|
From enrollement to five years of follow-up.
|
|
|
Five-year event-free survival
Aikaikkuna: From enrollement to five years of follow-up.
|
Event-free survival in patients managed through the CESAR care pathway compared with a propensity score-matched control population extracted from the French national health claims database.
|
From enrollement to five years of follow-up.
|
|
Area under the precision-recall curve (PR-AUC) of the artificial intelligence model for detecting cardiac involvement
Aikaikkuna: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Area under the receiver operating characteristic curve (ROC-AUC) of the artificial intelligence model for detecting cardiac involvement
Aikaikkuna: From enrollement to six months of follow-up.
|
From enrollement to six months of follow-up.
|
|
|
Duration of sick leave
Aikaikkuna: From enrollement to five years of follow-up.
|
Cumulative duration of sick leave during follow-up in days.
|
From enrollement to five years of follow-up.
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Yhteistyökumppanit
Yhteistyökumppanit
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Opiskelun aloitus
Ensisijainen valmistuminen (Arvioitu)
Ensisijainen valmistuminen
Opintojen valmistuminen (Arvioitu)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Verisuonisairaudet
- Sydän-ja verisuonitaudit
- Patologiset prosessit
- Sydänsairaudet
- Hengityselinten sairaudet
- Keuhkosairaudet
- Embolia ja tromboosi
- Embolia
- Sydänlihaksen iskemia
- Tromboosi
- Patologiset tilat, merkit ja oireet
- Sydämen vajaatoiminta
- Hypertensio
- Keuhkoveritulppa
- Laskimotromboosi
- Akuutti sepelvaltimo-oireyhtymä
- Rytmihäiriöt, sydän
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- APHP260122
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .